Company: GMRE
Filing Date: 2025-11-14
Form Type: 424B5
Source: 0001104659-25-112543
Chunk: 19

Company: Global Medical REIT Inc.
Filing Date: 2025-11-14
Form: 424B5
Chunk 19
---
 discouraging
a third party from seeking to acquire us or of delaying, deferring or preventing a Change of Control under circumstances that otherwise
could provide the holders of our common stock, Series A Preferred Stock and Series B Preferred Stock with the opportunity to
realize a premium over the then-current market price or that stockholders may otherwise believe is in their best interests.

<div align='center'>S-10</div>

The market price of common stock received in a conversion of our Series B Preferred Stock may decrease between the date received and the date the common stock is sold.

The market price of our common stock received
in a conversion may decrease between the date received and the date our common stock is sold. The stock markets, including the NYSE, have
experienced significant price and volume fluctuations. As a result, the market price of our common stock may be similarly volatile, and
recipients of our common stock may experience a decrease in the value of their shares, including decreases unrelated to our operating
performance or prospects. The price of our common stock could be subject to wide fluctuations in response to a number of factors, including
sales of common stock by other stockholders who received common stock upon conversion of their Series A Preferred Stock or Series B
Preferred Stock, our financial performance, government regulatory action or inaction, tax laws, interest rates and general market conditions
and other factors. See “— Shares of our Series B Preferred Stock are newly issued securities with no established trading
market, which may negatively affect their market value and your ability to transfer or sell your shares. We intend to apply to list our
Series B Preferred Stock on the NYSE, but we cannot assure you that the listing will be approved or that a trading market will develop
or be sustained.”

Because we conduct substantially all of our operations through our Operating Partnership, our ability to pay dividends on our Series B Preferred Stock depends almost entirely on the distributions we receive from our Operating Partnership. We may not be able to pay dividends regularly.

We may not be able to pay dividends on a regular
quarterly basis in the future. We intend to contribute the entire net proceeds from this offering to our Operating Partnership in exchange
for Series B Preferred OP Units that have substantially the same economic terms as the Series B Preferred Stock. Because we
conduct substantially all of our operations through our Operating Partnership, our ability to pay dividends on the Series B Preferred
Stock will depend almost entirely on payments and distributions we receive on our interests in our Operating Partnership. If our Operating